Review



csf2rb  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology csf2rb
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Csf2rb, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csf2rb/product/Santa Cruz Biotechnology
    Average 93 stars, based on 19 article reviews
    csf2rb - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma"

    Article Title: Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

    Journal: bioRxiv

    doi: 10.1101/2025.03.18.643177

    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Figure Legend Snippet: (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

    Techniques Used: Mutagenesis, Expressing, Migration, Transwell Migration Assay, Control, Injection, Staining, Concentration Assay



    Similar Products

    gene exp csf2rb mm00655745 m1  (Thermo Fisher)
    98
    Thermo Fisher gene exp csf2rb mm00655745 m1
    Gene Exp Csf2rb Mm00655745 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp csf2rb mm00655745 m1/product/Thermo Fisher
    Average 98 stars, based on 1 article reviews
    gene exp csf2rb mm00655745 m1 - by Bioz Stars, 2026-03
    98/100 stars
    		  Buy from Supplier
    cd131-deficient mice ( csf2rb +/− ) on a c57bl/6j background  (Shanghai Model Organisms Center)
    90
    Shanghai Model Organisms Center cd131-deficient mice ( csf2rb +/− ) on a c57bl/6j background
    Cd131 Deficient Mice ( Csf2rb +/− ) On A C57bl/6j Background, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd131-deficient mice ( csf2rb +/− ) on a c57bl/6j background/product/Shanghai Model Organisms Center
    Average 90 stars, based on 1 article reviews
    cd131-deficient mice ( csf2rb +/− ) on a c57bl/6j background - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    anti cd131  (Proteintech)
    93
    Proteintech anti cd131
    Anti Cd131, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd131/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti cd131 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    csf2rb  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology csf2rb
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Csf2rb, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csf2rb/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    csf2rb - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    gene exp csf2rb hs00166144 m1  (Thermo Fisher)
    85
    Thermo Fisher gene exp csf2rb hs00166144 m1
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Gene Exp Csf2rb Hs00166144 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp csf2rb hs00166144 m1/product/Thermo Fisher
    Average 85 stars, based on 1 article reviews
    gene exp csf2rb hs00166144 m1 - by Bioz Stars, 2026-03
    85/100 stars
    		  Buy from Supplier
    csf2rb forward (gcaugucugugauccaccatt)  (Shanghai GenePharma)
    90
    Shanghai GenePharma csf2rb forward (gcaugucugugauccaccatt)
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Csf2rb Forward (Gcaugucugugauccaccatt), supplied by Shanghai GenePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csf2rb forward (gcaugucugugauccaccatt)/product/Shanghai GenePharma
    Average 90 stars, based on 1 article reviews
    csf2rb forward (gcaugucugugauccaccatt) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    csf2rb -/- mice (zurich, b6.129s1- csf2rb tm1cgb /j  (Jackson Laboratory)
    90
    Jackson Laboratory csf2rb -/- mice (zurich, b6.129s1- csf2rb tm1cgb /j
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Csf2rb / Mice (Zurich, B6.129s1 Csf2rb Tm1cgb /J, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csf2rb -/- mice (zurich, b6.129s1- csf2rb tm1cgb /j/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    csf2rb -/- mice (zurich, b6.129s1- csf2rb tm1cgb /j - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    cd131  (Proteintech)
    93
    Proteintech cd131
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Cd131, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd131/product/Proteintech
    Average 93 stars, based on 1 article reviews
    cd131 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    csf2rb -/- mice  (Jackson Laboratory)
    90
    Jackson Laboratory csf2rb -/- mice
    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of <t>CSF2RB</t> mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.
    Csf2rb / Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/csf2rb -/- mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    csf2rb -/- mice - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

    Journal: bioRxiv

    Article Title: Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

    doi: 10.1101/2025.03.18.643177

    Figure Lengend Snippet: (A) Proportion of mutation types across recurrently mutated genes. (B) Lollipop diagram depicting the distribution of CSF2RB mutations in our in-house cohort. (C) WB analysis of CSF2RB expression and phosphorylation status of STAT5 in the L-428 model. Representative images are shown (left). Densitometry analysis was carried out by Image Lab (right). Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test. (D) Top pathways from LymphoChip upregulated in E788* cells compared to WT cells in the L-428 model. (E) Heatmap showing transcript levels of genes in the L-428 model. Genes with consistent expression changes (absolute fold change ≥ 1.4) across all three experimental models (L-428, U-HO1 + IL-3, U-HO1 + IL-5) are shown. (F) TARC and IL-13 concentrations in supernatant of L-428 model at baseline. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way ANOVA followed by Dunnett’s multiple comparisons test (TARC), and a negative binomial regression model to account for overdispersion in the data (IL-13). (G) TARC and IL-13 concentrations in supernatant of L-428 (left) model treated with pacritinib (0.5 μM) for 48 hours, and U-HO1 (right) model in the presence of IL-3 (1 ng/mL) or IL-5 (1 ng/mL) treated with or without pacritinib (0.5 μM) for 48 hours. Data are presented as mean ± SEM. Pre- and post-treatment comparisons were conducted using an unpaired, two-sided t -test for each cell type. (H) CCR4+CD4+ T cell migration towards L-428 CSF2RB WT or E788* supernatant in a transwell migration assay, showing the percentage of migrated cells relative to the input control. A paired, two-sided t -test was used to compare the two conditions. Data are presented as mean ± SEM (n=4). (I) Spleen tissues from humanized mouse model, sacrificed at 12 weeks after CB injection, were stained with hematoxylin and eosin (H&E), CD30, CD4, PAX5, and FOXP3. The image is presented at a magnification of 20X. (J) Percentage of CD4+CD25+FOXP3+ Tregs identified in spleen of humanized CNW mice engrafted with L-428 CSF2RB WT or E788* cells by FCM. An unpaired, two-sided t -test was used to compare the two conditions, and data are shown as the mean ± SEM (n=6 for WT and n=5 for E788*). (K) Bar graph depicts serum TARC concentration from CNW mice engrafted L-428 WT (n=6) and E788* (n=5) cells, sacrificed at 12 weeks after CB injection. An unpaired, two-sided t -test was used to compare the two conditions. The data are shown as mean ± SEM.

    Article Snippet: Immunoblotting was performed as previously described( Alig et al ., 2023 ) using the following primary antibodies: STAT1 Rabbit mAb (D1K9Y), STAT3 Mouse mAb (124H6), STAT6 Rabbit mAb (D3H4), AKT(pan) Rabbit mAb (C67E7), Phospho-STAT1 (Y701) Rabbit mAb (58D6), Phospho-STAT3 (Y705) Rabbit mAb (D3A7), Phospho-STAT5 (Y694) Rabbit mAb (C11C5), Phospho-STAT6 (Y641) Rabbit mAb (C11A12), Phospho-AKT (S473) Rabbit mAb (193H12), GAPDH Rabbit mAb (14C10) (all from Cell Signaling Technology, dilution 1:1000), STAT5 Rabbit polyclonalAb (C-17) (dilution 1:5000), CSF2RB (IL-3/IL-5/GM-CSFRβ Mouse mAb (A-3) (dilution 1:100) (Santa Cruz Biotechnology), followed by secondary staining using anti-Mouse (dilution 1:10000; Promega, catalog no. W4021) or Rabbit IgG (H+L) HRP conjugate (dilution 1:5000; Promega, catalog no. W4011), and detected using Amersham ECL Detection Reagents (Cytiva, catalog no. RPN3004).

    Techniques: Mutagenesis, Expressing, Migration, Transwell Migration Assay, Control, Injection, Staining, Concentration Assay